Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer.

We examined the specificity of different cyclin E antibodies and concordance between immunohistochemical and Western blot analyses for each antibody in a panel of 14 breast cell lines. Nuclear versus cytoplasmic staining of cyclin E readily differentiated full-length from LMW-E, respectively. We also evaluated the expression of cyclin E and p-CDK2 in 1676 human breast carcinoma cases by using immunohistochemical analysis. Cytoplasmic cyclin E correlated strongly with cytoplasmic p-CDK2 (P < 0.0001), increasing tumor grade, negative estrogen/progesterone status, and human epidermal growth factor receptor 2 positivity (all P < 0.0001). In multivariable analysis, cytoplasmic cyclin E plus phosphorylated CDK2 (as one variable) predicted breast cancer recurrence-free and overall survivals. These results suggest that altered cellular localization of cyclin E and p-CDK2 can be readily determined with immunohistochemistry and used as clinical biomarkers for aggressive breast cancer.
PMID: 27182644 [PubMed - as supplied by publisher]

Source: The American Journal of Pathology - May 12, 2016 Category: Pathology Authors: Karakas C, Biernacka A, Bui T, Sahin A, Yi M, Akli S, Schafer J, Alexander A, Adjapong O, Hunt KK, Keyomarsi K Tags: Am J Pathol Source Type: research